mmitteeAnalyses of both trials indi

mmittee
Analyses of both trials indicate that observed reduction in prostate cancer risk on taking finasteride and dutasteride was limited to tumors that had mGS of ≤ 6.
Data collected in REDUCE trial indicates that 80% of these cancers belong to ‘very low risk’ category (Epstein pathological criteria) and hence, their clinical significance is negligible.
Use of 5 α reductase inhibitor drugs may hence prevent 3 to 4 low-grade cancers at the expense of one high-grade prostate cancer.
The committee concluded that both drugs do not have significant risk-benefit profile for preventing prostate cancer in healthy men.

Результаты (английский) 1:

mmitteeAnalyses of both trials indicate that the observed reduction in prostate cancer risk on taking finasteride and dutasteride was limited to tumors that had mGS of ≤ 6.Data collected in the REDUCE trial indicates that 80% of these cancers belong to very low ' risk ' category (Epstein pathological criteria) and hence, their clinical significance is negligible.Use of 5 α reductase an drugs may hence prevent 3 to 4 low grade cancers at the expense of one high grade prostate cancer.The committee concluded that both drugs do not have significant risk-benefit profile for preventing prostate cancer in healthy men.

Результаты (английский) 2:

mmittee
Analyses of both trials indicate that observed reduction in prostate cancer risk on taking finasteride and dutasteride was limited tumors that had to mGS of ≤ 6.
Data collected in REDUCE trial indicates that 80% of these cancers belong to 'very low risk' category ( Epstein pathological criteria) and hence, their clinical significance is negligible.
Use of 5 α reductase inhibitor drugs may hence prevent 3 to 4 low-grade cancers at the expense of one high-grade prostate cancer.
The committee concluded that both drugs do not have significant risk-benefit profile for preventing prostate cancer in healthy men.

Результаты (английский) 3:

mmittee
analyses of both trials indicate that the observed reduction in prostate cancer risk on taking finasteride and dutasteride was limited to tumors that had mGS of < 6.
data collected in REDUCE trial indicates that 80% of these cancers belong to the 'low risk' category (epstein and pathological criteria) and hence, their clinical significance is table.
use of 5 various reductase inhibitor drugs may hence into 3 to 4 low - or cancers at the expense of a high - or prostate cancer.
the committee concluded that both drugs do not have significant risk - benefit profile for preventing prostate cancer in healthy men.